Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 15, 2011

Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy

  • Enobia selected Lonza for the production of its bone-targeted enzyme-replacement therapy ENB-0040, under investigation for the treatment of hypophosphatasia (HPP). Lonza will provide process validation and commercial manufacturing at its large-scale biologics site in Portsmouth, NH, with an option to extend production to a second Lonza site.

    HPP is caused by a deficiency in the tissue nonspecific form of alkaline phosphatase (TNSALP), an enzyme that plays a key role in regulating bone mineralization. Without TNSALP, inorganic pyrophosphate accumulates extracellulary and inhibits skeletal mineralization, leading to rickets in pediatric patients or osteomalacia in adults. ENB-0040 is proposed to directly target functional alkaline phosphatase to the patient’s bones to help correct the enzyme deficiency.

    Enobia recently completed a Phase II juvenile study. It met the primary endpoint, demonstrating a statistically significant improvement in rickets when compared with historical matched cohort controls. Rickets, a softening and weakening of the bones, is often seen in children with HPP and can lead to fractures, pain, and deformity.

    The company previously reported the successful completion of a trial in infants. Participants reportedly continue to demonstrate functional and respiratory improvements in longer-term follow-up. A Phase II study in adolescents and adults with HPP is ongoing.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »